HDAC6-IN-83

HDAC6-IN-83 (Compound P21) (0.27-5.92 μM; 48 h) exhibits broad-spectrum antiproliferative activity against various cancer cell lines, with IC₅₀ values ranging from 0.27 μM to 5.92 μM, and shows favorable safety profiles in normal HEK293 cells^[1].
HDAC6-IN-83 (0.01-0.2 μM; 12 h) selectively increases the acetylation level of α-tubulin in RPMI 8226 cells after 12 h of treatment, without affecting the acetylation of histone H3^[1].
HDAC6-IN-83 (0.1-10 μM; 24-48 h) dose-dependently inhibits the invasive ability of A549 cells, with significant inhibition observed at concentrations as low as 1 μM^[1].
HDAC6-IN-83 (0.01-1.25 μM; 24 h) dose-dependently induces apoptosis in Jurkat cells^[1].
HDAC6-IN-83 (0.05-0.25 μM; 24 h) induces G₂/M cell cycle arrest in Jurkat cells following treatment with 0.25 μM for 24 h^[1].
HDAC6-IN-83 (0.1-10 μM; 6 h) dose-dependently inhibits angiogenesis in human umbilical vein endothelial cells (HUVEC)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.